Trials / Unknown
UnknownNCT00591422
Phase I Study of Oral Darinaparsin (ZIO-101-C)in Advanced Solid Tumors and Non-Hodgkin's Lymphomas
Phase I Study of Oral Darinaparsin (ZIO-101-C) in Advanced Solid Tumors and Non-Hodgkin's Lymphomas
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Alaunos Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study of Dariniparsin (ZIO-101-C) in Advanced Solid Tumors and Non-Hodgkin's Lymphomas
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZIO-101-C (Darinaparsin) | Capsule, Dose escalation study from 100 mg to 1000 mg (or Maximum Tolerated Dose). 3 times weekly (\>36 hours between doses) for 3 weeks with 1 week rest. |
Timeline
- Start date
- 2007-08-01
- Primary completion
- 2013-06-01
- Completion
- 2013-06-01
- First posted
- 2008-01-11
- Last updated
- 2012-07-19
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00591422. Inclusion in this directory is not an endorsement.